##### Table X Targeted Immunomodulators for Moderate-to-Severe Plaque Psoriasis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mechanism of Action | Name and Company | FDA approval for plaque psoriasis | Market availability | Dosing |
| TNFα | adalimumab / Humira®  Abott | Reference Biologic  2008/01/18 | Available | 80mg subcutaneously, then 40mg every other week starting 1 week after initial dose |
| adalimumab-atto / Amjevita®  Amgen | Biosimilar  2016/09/23 | Not launched | 80mg subcutaneously, then 40mg every other week starting 1 week after initial dose |
| adalimumab-adbm / Cyltezo®  Boehringer Ingelheim | Biosimilar  2017/08/31 | Not launched | 80mg subcutaneously, then 40mg every other week starting 1 week after initial dose |
| etanercept /  Enbrel®  Amgen | Reference Biologic  2004/04/30 | Available | 50mg subcutaneously 2x/week for 3 months, then 50mg 1x/week |
| etanercept-szzs / Erelzi®  Novartis | Biosimilar  2016/08/30 | Not launched | 50mg subcutaneously 2x/week for 3 months, then 50mg 1x/week |
| infliximab / Remicade®  Janssen | Reference Biologic  2006/09/26 | Available | 5mg/kg intravenously at weeks 0, 2, and 6, then every 8 weeks |
| infliximab-dyyb / Inflectra®  Pfizer | Biosimilar  2016/04/05 | Available since 2016-10-17 | 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks |
| infliximab-abda, Renflexis®  Merck | Biosimilar  2017/04/24 | Available since 2017/07/24 | 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks |
| infliximab-qbtx /  Ixifi®  Pfizer | Biosimilar  2017/12/13 | Not launched | 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks |
| certolizumab pego / Cimzia®  UCB | Reference Biologic, under FDA review for moderate to severe psoriasis indication | Available for psoriatic arthritis | n/a |
| IL 12/23 | ustekinumab / Stelara®  Janssen | Reference Biologic  2009/09/25 | Available | Patients ≤100kg/>100kg: 45mg/90mg subcutaneously at week 0 and 4, then every 12 weeks |
| IL 23 | guselkumab/ Tremfya®  Janssen | Reference Biologic 2017/07/13 | Available | 100mg subcutaneously at weeks 0, week 4, then every 8 weeks |
| tildrakizumab-asmn / Ilumya®  Sun/Merck | Reference Biologic  2018/03/2018 | Available ? | 100 mg subcutaneously at weeks 0, 4, then every twelve weeks |
|  | Risankizumab  Abbvie | FDA submission to be confirmed |  |  |
| IL 17-A | secukinumab / Cosentyx®  Novartis | Reference Biologic  2015/01/21 | Available | 300mg subcutaneously at weeks 0, 1, 2, 3, 4 then 300mg every 4 weeks |
| ixekizumab /  Taltz®  Eli Lilly | Reference Biologic, 2016/03/22 | Available | 160mg subcutaneously at week 0, then 80mg at weeks 2, 4, 6, 8, 10, 12, then 80mg every 4 weeks |
| brodalumab /  Siliq®  Valeant | Reference Biologic  2017/02/15 | Available | 210mg subcutaneously, every 2 weeks\* |
| PDE-4 | Apremilast /  Otezla®  Celgene | Reference Biologic  2014/09/23 | Available | 5-day titration then 30mg orally 2x/day thereafter |